Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States.

ABSTRACT:

Purpose

Patients receiving treatment for acromegaly often experience significant associated comorbidities for which they are prescribed additional medications. We aimed to determine the real-world prevalence of comorbidities and concomitant medications in patients with acromegaly, and to investigate the association between frequency of comorbidities and number of concomitantly prescribed medications.

Methods

Administrative claims data were obtained from the IBM® MarketScan® database for a cohort of patients with acromegaly, identified by relevant diagnosis codes and acromegaly treatments, and a matched control cohort of patients without acromegaly from January 2010 through April 2020. Comorbidities were identified based on relevant claims and assessed for both cohorts.

Re

SUBMITTER: Fleseriu M 

PROVIDER: S-EPMC8894179 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature